ArticleThe Journal of pharmacology and experimental therapeutics2016
Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys.
Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 57 citations in OpenAlex.
- Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder.Drug and alcohol dependence · 2024Trial
- The 5-HTPharmacology research & perspectives · 2021Trial
- Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.Drug and alcohol dependence · 2020Trial
- The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.Pharmacology, biochemistry, and behavior · 2019Trial
- Lorcaserin modulation of semantic drug cue-elicited effective brain connectivity in persons with cocaine and opioid use disorders.Psychiatry research. Neuroimaging · 2025Article
- Mechanistic and translational insights from preclinical cocaine choice procedures on the economic substitutability of cocaine and nondrug reinforcers.Neuroscience and biobehavioral reviews · 2025Review
- Review
- Effects of access condition on substance use disorder-like phenotypes in male and female rats self-administering MDPV or cocaine.Drug and alcohol dependence · 2024Article
- Effects of access condition on substance use disorder-like phenotypes in male and female rats self-administering MDPV or cocaine.bioRxiv : the preprint server for biology · 2024Article
- 3,4-Methylenedioxypyrovalerone High-Responder Phenotype as a Tool to Evaluate Candidate Medications for Stimulant Use Disorder.The Journal of pharmacology and experimental therapeutics · 2023Article
- Evaluation of the 5-HTPharmacological reports : PR · 2023Article
- The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal.Pharmacology, biochemistry, and behavior · 2023Article
- Confronting the challenge of failed translation in medications development for substance use disorders.Pharmacology, biochemistry, and behavior · 2021Article
- Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys.Drug and alcohol dependence · 2021Article
- Converging vulnerability factors for compulsive food and drug use.Neuropharmacology · 2021Review
- 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.Addiction biology · 2021Article
- Improving translation of animal models of addiction and relapse by reverse translation.Nature reviews. Neuroscience · 2020Review
- Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.Neuropharmacology · 2020Article
- Adjunctive effect of the serotonin 5-HTNeuropharmacology · 2020Article
- Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys.Drug and alcohol dependence · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Cocaine abuse and obesity are serious public health problems, and studies suggest that both dopamine and serotonin systems are involved in regulating the consumption of drugs and food. Lorcaserin has serotonin (5-HT)2C receptor agonist actions, is approved by the U.S. Food and Drug Administration for treating obesity, and might be effective for treating cocaine abuse. These studies characterized the pharmacokinetic and behavioral profiles of lorcaserin (intragastric administration) and determined the effectiveness of lorcaserin to alter discriminative stimulus and reinforcing effects of cocaine (intravenous administration) in rhesus monkeys. Administered acutely, lorcaserin dose-dependently increased the occurrence of yawning while decreasing spontaneous activity and operant responding for food. These effects appeared within 30-60 minutes of administration and began to dissipate by 240 minutes, a time course closely matching plasma concentrations of lorcaserin. In monkeys discriminating cocaine from saline, lorcaserin alone did not occasion cocaine-appropriate responding but shifted the cocaine dose-response curve to the right and down in two of three monkeys. When administered acutely, lorcaserin dose-dependently decreased the rate at which monkeys responded for infusions of cocaine. When administered chronically, 3.2 mg/kg lorcaserin reduced the rate of cocaine-maintained responding by 50% for the duration of a 14-day treatment period. Together, these results show that lorcaserin attenuates the discriminative stimulus effects of cocaine after acute administration and the reinforcing effects of cocaine after acute and repeated administration, consistent with the view that it might have utility in treating cocaine abuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.